IDRA

Aceragen, Inc.

A clinical-stage biopharmaceutical company that develops therapies for rare pulmonary and rheumatic diseases, including an investigational enzyme-replacement treatment for Farber disease, a rare genetic disorder. Founded in 2021 by industry veteran John Taylor, the private startup was acquired in 2022 by Idera Pharmaceuticals, which then renamed itself Aceragen. The ticker symbol ACGN is simply an abbreviation of the company's own name, spelled out as "ACerageN."